[1]
|
Medjeral-Thomas, N.R. and O’Shaughnessy, M.M. (2020) Complement in IgA Nephropathy: The Role of Complement in the Pathogenesis, Diagnosis, and Future Management of IgA Nephropathy. Advances in Chronic Kidney Disease, 27, 111-119. https://doi.org/10.1053/j.ackd.2019.12.004
|
[2]
|
Kiryluk, K., Li, Y., Sanna-Cherchi, S., et al. (2012) Ge-ographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk Analysis. PLOS Genetics, 8, e1002765.
https://doi.org/10.1371/journal.pgen.1002765
|
[3]
|
Li, L.S. and Liu, Z.H. (2004) Epidemiologic Data of Renal Diseases from a Single Unit in China: Analysis Based on 13,519 Renal Biopsies. Kidney International, 66, 920-923. https://doi.org/10.1111/j.1523-1755.2004.00837.x
|
[4]
|
Pattrapornpisut, P., Avila-Casado, C. and Reich, H.N. (2021) IgA Nephropathy: Core Curriculum 2021. American Journal of Kidney Diseases, 78, 429-441. https://doi.org/10.1053/j.ajkd.2021.01.024
|
[5]
|
Suzuki, K., Honda, K., Tanabe, K., et al. (2003) Incidence of La-tent Mesangial IgA Deposition in Renal Allograft Donors in Japan. Kidney International, 63, 2286-2294. https://doi.org/10.1046/j.1523-1755.63.6s.2.x
|
[6]
|
Rajasekaran, A., Julian, B.A. and Rizk, D.V. (2021) IgA Nephropathy: An Interesting Autoimmune Kidney Disease. The American Journal of the Medical Sciences, 361, 176-194. https://doi.org/10.1016/j.amjms.2020.10.003
|
[7]
|
Magistroni, R., D’agati, V.D., Appel, G.B., et al. (2015) New Developments in the Genetics, Pathogenesis, and Therapy of IgA Nephropathy. Kidney International, 88, 974-989. https://doi.org/10.1038/ki.2015.252
|
[8]
|
He, B., Xu, W., Santini, P.A., et al. (2007) Intestinal Bacteria Trigger T Cell-Independent Immunoglobulin A2 Class Switching by Inducing Epithelial-Cell Secretion of the Cytokine APRIL. Immunity, 26, 812-826.
https://doi.org/10.1016/j.immuni.2007.04.014
|
[9]
|
Lehrer, R.I. and Lu, W. (2012) α-Defensins in Human Innate Immunity. Immunological Reviews, 245, 84-112.
https://doi.org/10.1111/j.1600-065X.2011.01082.x
|
[10]
|
Sanchez-Rodriguez, E., Southard, C.T. and Kiryluk, K. (2021) GWAS-Based Discoveries in IgA Nephropathy, Membranous Nephropathy, and Steroid-Sensitive Nephrotic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 16, 458-466. https://doi.org/10.2215/CJN.14031119
|
[11]
|
Hiki, Y., Odani, H., Takahashi, M., et al. (2001) Mass Spectrometry Proves Under-O-Glycosylation of Glomerular IgA1 in IgA Nephropathy. Kidney International, 59, 1077-1085.
https://doi.org/10.1046/j.1523-1755.2001.0590031077.x
|
[12]
|
Allen, A.C., Bailey, E.M. and Brenchley, P.E. (2001) Mesangial IgA1 in IgA Nephropathy Exhibits Aberrant O-Glycosylation: Observations in Three Patients. Kidney Inter-national, 60, 969-973.
https://doi.org/10.1046/j.1523-1755.2001.060003969.x
|
[13]
|
He, J.W., Zhou, X.J., Lv, J.C., et al. (2020) Perspec-tives on How Mucosal Immune Responses, Infections and Gut Microbiome Shape IgA Nephropathy and Future Thera-pies. Theranostics, 10, 11462-11478.
https://doi.org/10.7150/thno.49778
|
[14]
|
Aguilera, M., Cerda-Cuellar, M. and Martinez, V. (2015) Antibi-otic-Induced Dysbiosis Alters Host-Bacterial Interactions and Leads to Colonic Sensory and Motor Changes in Mice. Gut Microbes, 6, 10-23.
https://doi.org/10.4161/19490976.2014.990790
|
[15]
|
Yang, C., Mogno, I., Contijoch, E.J., et al. (2020) Fecal IgA Levels Are Determined by Strain-Level Differences in Bacteroides ovatus and Are Modifiable by Gut Microbiota Ma-nipulation. Cell Host & Microbe, 27, 467-475.E6.
https://doi.org/10.1016/j.chom.2020.01.016
|
[16]
|
Kidney Disease: Improving Global Outcomes Glomerular Dis-eases Work Group (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 100, S1-S276.
|
[17]
|
Robert, T., Cambier, A. and Hertig, A. (2016) Intensive Supportive Care Plus Immu-nosuppression in IgA Nephropathy. New England Journal of Medicine, 374, 991-993. https://doi.org/10.1056/NEJMc1600141
|
[18]
|
Le, W., Liang, S., Hu, Y., et al. (2012) Long-Term Renal Survival and Related Risk Factors in Patients with IgA Nephropathy: Results from a Cohort of 1155 Cases in a Chinese Adult Population. Nephrology, Dialysis, Transplantation, 27, 1479-1485. https://doi.org/10.1093/ndt/gfr527
|
[19]
|
Geng, D.F., Sun, W.F., Yang, L., et al. (2014) Antiproteinuric Effect of Angiotensin Receptor Blockers in Normotensive Pa-tients with Proteinuria: A Meta-Analysis of Randomized Controlled Trials. Journal of the Renin-Angiotensin- Aldoste-rone System, 15, 44-51. https://doi.org/10.1177/1470320312474054
|
[20]
|
Makani, H., Bangalore, S., Desouza, K.A., et al. (2013) Efficacy and Safety of Dual Blockade of the Renin-Angiotensin System: Meta-Analysis of Random-ised Trials. British Medical Journal, 346, f360.
https://doi.org/10.1136/bmj.f360
|
[21]
|
Lennartz, D.P., Seikrit, C., Wied, S., et al. (2020) Single versus Dual Blockade of the Renin-Angiotensin System in Patients with IgA Nephropathy. Journal of Nephrology, 33, 1231-1239. https://doi.org/10.1007/s40620-020-00836-8
|
[22]
|
Huo, Z., Ye, H., Ye, P., et al. (2021) Comparative Efficacy of Different Renin Angiotensin System Blockade Therapies in Patients with IgA Nephropathy: A Bayesian Network Me-ta-Analysis of 17 RCTs. PeerJ, 9, e11661.
https://doi.org/10.7717/peerj.11661
|
[23]
|
Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group (2012) KDIGO 2012 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Interna-tional, 2, S1-143.
|
[24]
|
Floege, J. (2019) Antimalarials in IgA Nephropathy: Did Our Supportive Therapy Armamentar-ium Just Increase? American Journal of Kidney Diseases, 74, 6-8. https://doi.org/10.1053/j.ajkd.2019.02.022
|
[25]
|
Rauen, T. and Floege, J. (2017) Inflammation in IgA Nephropathy. Pediatric Nephrology, 32, 2215-2224.
https://doi.org/10.1007/s00467-017-3628-1
|
[26]
|
Lv, J., Zhang, H., Chen, Y., et al. (2009) Combination Therapy of Prednisone and ACE Inhibitor versus ACE-Inhibitor Therapy Alone in Patients with IgA Nephropathy: A Random-ized Controlled Trial. American Journal of Kidney Diseases, 53, 26-32. https://doi.org/10.1053/j.ajkd.2008.07.029
|
[27]
|
Rauen, T., Wied, S., Fitzner, C., et al. (2020) After Ten Years of Follow-Up, No Difference between Supportive Care Plus Immunosuppression and Supportive Care Alone in IgA Nephropathy. Kidney International, 98, 1044-1052.
https://doi.org/10.1016/j.kint.2020.04.046
|
[28]
|
Lv, J., Zhang, H., Wong, M.G., et al. (2017) Effect of Oral Methylprednisolone on Clinical Outcomes in Patients with IgA Nephropathy: The TESTING Randomized Clinical Trial. Journal of the American Medical Association, 318, 432-442.
https://doi.org/10.1001/jama.2017.9362
|
[29]
|
Wong, M.G., Lv, J., Hladunewich, M.A., et al. (2021) The Thera-peutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. American Journal of Nephrology, 52, 827-836.
https://doi.org/10.1159/000519812
|
[30]
|
刘开翔, 龚蓉, 谢席胜. 单纯糖皮质激素治疗IgA肾病的系统评价[J]. 中国中西医结合肾病杂志, 2020, 21(4): 321-327.
|
[31]
|
Nagasawa, Y., Yamamoto, R., Shinzawa, M., et al. (2020) Ef-ficacy of Corticosteroid Therapy for IgA Nephropathy Patients Stratified by Kidney Function and Proteinuria. Clinical and Experimental Nephrology, 24, 927-934.
https://doi.org/10.1007/s10157-020-01918-4
|
[32]
|
Natale, P., Palmer, S.C., Ruospo, M., et al. (2020) Immunosup-pressive Agents for Treating IgA Nephropathy. Cochrane Database of Systematic Reviews, 3, CD003965. https://doi.org/10.1002/14651858.CD003965.pub3
|
[33]
|
Fellström, B.C., Barratt, J. and Cook, H. (2017) Target-ed-Release Budesonide versus Placebo in Patients with IgA Nephropathy (NEFIGAN): A Double-Blind, Randomised, Placebo-Controlled Phase 2b Trial. The Lancet, 389, 2117-2127.
https://doi.org/10.1016/S0140-6736(17)30550-0
|
[34]
|
Sweden, S. (2020) Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial. EU Market Abuse Regulation.
|
[35]
|
Liu, L.J., Yang, Y.Z., Shi, S.F., et al. (2019) Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. American Journal of Kidney Diseases, 74, 15-22.
https://doi.org/10.1053/j.ajkd.2019.01.026
|
[36]
|
Yang, Y.Z., Liu, L.J., Shi, S.F., et al. (2018) Effects of Hy-droxychloroquine on Proteinuria in Immunoglobulin A Nephropathy. American Journal of Nephrology, 47, 145-152. https://doi.org/10.1159/000487330
|
[37]
|
Yang, Y.Z., Chen, P., Liu, L.J., et al. (2019) Comparison of the Effects of Hydroxychloroquine and Corticosteroid Treatment on Proteinuria in IgA Nephropathy: A Case-Control Study. BMC Nephrology, 20, Article No. 297.
https://doi.org/10.1186/s12882-019-1488-6
|
[38]
|
Tang, C., Lv, J.C., Shi, S.F., et al. (2020) Effect of Hy-droxychloroquine in Patients with IgA Nephropathy with Insufficient Responses to Immunosuppressive Therapy: A Retrospective Case-Control Study. BMC Nephrology, 21, Article No. 469. https://doi.org/10.1186/s12882-020-02141-9
|
[39]
|
Yu, Y., Peng, J. and Zhou, L. (2020) Short-Term and Long-Term Efficacy, Safety Assessment and Independent Prognostic Risk Factors of Hydroxychloroquine in the Treat-ment of IgA Nephropathy. Acta Medica Mediterranea, 36, 1345-1350.
|
[40]
|
Tang, C., Lv, J.C., Shi, S.F., et al. (2021) Long-Term Safety and Efficacy of Hydroxychloroquine in Patients with IgA Nephropathy: A Single-Center Experience. Journal of Nephrology, 35, 429-440.
https://doi.org/10.1007/s40620-021-00988-1
|
[41]
|
Tang, C., Si, F.L., Yao, Y.X., et al. (2022) The Efficacy and Safety of Hydroxychloroquine in Pregnant Patients with IgA Nephropathy: A Retrospective Cohort Study. Nephrology, 27, 155-161. https://doi.org/10.1111/nep.13991
|
[42]
|
陈香美, 陈仆, 汤力. 吗替麦考酚酯治疗重症IgA肾病的随机对照试验[J]. 中华医学杂志, 2002, 82(12): 796-801.
|
[43]
|
Tang, S., Leung, J.C.K. and Chan, L.Y.Y. (2005) Mycophenolate Mofetil Alleviates Persistent Proteinuria in IgA Nephropathy. Kidney International, 68, 802-812. https://doi.org/10.1111/j.1523-1755.2005.00460.x
|
[44]
|
Hou, J.H., Le, W.B., Chen, N., et al. (2017) Mycopheno-late Mofetil Combined With Prednisone versus Full-Dose Prednisone in IgA Nephropathy with Active Proliferative Le-sions: A Randomized Controlled Trial. American Journal of Kidney Diseases, 69, 788-795. https://doi.org/10.1053/j.ajkd.2016.11.027
|
[45]
|
Zhao, J., Ma, F., Bai, M., et al. (2021) Low-Dose Corticosteroid Combined With Mycophenolate Mofetil for IgA Nephropathy with Stage 3 or 4 CKD: A Retrospective Cohort Study. Clinical Therapeutics, 43, 859-870.
https://doi.org/10.1016/j.clinthera.2021.03.009
|
[46]
|
Maes, B.D., Oyen, R. and Claes, K. (2004) Mycophenolate Mofetil in IgA Nephropathy: Results of a 3-Year Prospective Placebo-Controlled Randomized Study. Kidney Interna-tional, 65, 1842-1849.
https://doi.org/10.1111/j.1523-1755.2004.00588.x
|
[47]
|
Frisch, G., Lin, J., Rosenstock, J., et al. (2005) Mycophe-nolate Mofetil (MMF) vs Placebo in Patients with Moderately Advanced IgA Nephropathy: A Double-Blind Random-ized Controlled Trial. Nephrology, Dialysis, Transplantation, 20, 2139-2145. https://doi.org/10.1093/ndt/gfh974
|
[48]
|
Lafayette, R.A., Canetta, P.A., Rovin, B.H., et al. (2017) A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. Journal of the American So-ciety of Nephrology: JASN, 28, 1306-1313.
https://doi.org/10.1681/ASN.2016060640
|
[49]
|
Fenogli, R., Sciascia, S. and Naretto, C. (2020) Rituximab in Se-vere Immunoglobulin-A Vasculitis (Henoch-Schönlein) with Aggressive Nephritis. Clinical and Experimental Rheuma-tology, 38, 195-200.
|
[50]
|
Tan, S.L., Potezny, T. and Li, J.Y. (2021) The Successful Use of Rituximab in Crescentic IgA Nephropathy with Concurrent ANCA Positivity. Nephrology, 27, 216-217. https://doi.org/10.1111/nep.13950
|
[51]
|
Chancharoenthana, W., Townamchai, N., Leelahavanichkul, A., et al. (2017) Rituximab for Recurrent IgA Nephropathy in Kidney Transplantation: A Report of Three Cases and Proposed Mechanisms. Nephrology, 22, 65-71.
https://doi.org/10.1111/nep.12722
|
[52]
|
Dhillon, S. (2021) Telitacicept: First Approval. Drugs, 81, 1671-1675. https://doi.org/10.1007/s40265-021-01591-1
|
[53]
|
Samy, E., Wax, S., Huard, B., et al. (2017) Targeting BAFF and APRIL in Systemic Lupus Erythematosus and Other Antibody-Associated Diseases. International Reviews of Immunol-ogy, 36, 3-19.
https://doi.org/10.1080/08830185.2016.1276903
|
[54]
|
Parodis, I., Stockfelt, M. and Sjowall, C. (2020) B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice. Frontiers in Medicine, 7, Article No. 316. https://doi.org/10.3389/fmed.2020.00316
|
[55]
|
Lv, J., Liu, L. and Hao, C.M. (2021) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of Telitacicept in Patients with IgA Nephropathy and Persistent Proteinuria. Pro-ceedings of the ASN Kidney Week 2021, San Diego, 4-7 November 2021.
|
[56]
|
Mosenzon, O., Wiviott, S.D., Cahn, A., et al. (2019) Effects of Dapagliflozin on Development and Progression of Kidney Disease in Patients with Type 2 Diabe-tes: An Analysis from the DECLARE-TIMI 58 Randomised Trial. The Lancet Diabetes & Endocrinology, 7, 606-617. https://doi.org/10.1016/S2213-8587(19)30180-9
|
[57]
|
Heerspink, H.J.L., Stefansson, B.V., Correa-Rotter, R., et al. (2020) Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine, 383, 1436-1446. https://doi.org/10.1056/NEJMoa2024816
|
[58]
|
Cherney, D.Z.I., Dekkers, C.C.J., Barbour, S.J., et al. (2020) Ef-fects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-Diabetic Patients with Chronic Kidney Disease (DIAMOND): A Randomised, Double-Blind, Crossover Trial. The Lancet Diabetes & Endocrinology, 8, 582-593. https://doi.org/10.1016/S2213-8587(20)30162-5
|